These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 32961833

  • 1. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
    Leelawattanachai P, Wattanavijitkul T, Paiboonvong T, Plongla R, Chatsuwan T, Usayaporn S, Nosoongnoen W, Montakantikul P.
    Antibiotics (Basel); 2020 Sep 18; 9(9):. PubMed ID: 32961833
    [Abstract] [Full Text] [Related]

  • 2. Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection.
    Kanchanasurakit S, Santimaleeworagun W, McPherson CE, Piriyachananusorn N, Boonsong B, Katwilat P, Saokaew S.
    Infect Chemother; 2020 Dec 18; 52(4):516-529. PubMed ID: 33124216
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V, Docobo-Pérez F, Sojo J, Morales I, Lupión C, Martín D, Cameán M, Hope W, Pascual Á, Rodríguez-Baño J.
    Clin Microbiol Infect; 2018 Nov 18; 24(11):1177-1183. PubMed ID: 29649596
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital.
    Nasomsong W, Nulsopapon P, Changpradub D, Pongchaidecha M, Pungcharoenkijkul S, Juntanawiwat P, Simsiriporn W, Santimaleeworagun W.
    Drug Des Devel Ther; 2021 Nov 18; 15():3095-3104. PubMed ID: 34295150
    [Abstract] [Full Text] [Related]

  • 6. Amoxicillin and penicillin G dosing in pediatric community-acquired pneumococcal pneumonia in the era of conjugate pneumococcal vaccines.
    Huynh D, Tung N, Dam Q, Tran T, Hulten KG, Harrison CJ, Kaplan SL, Nguyen A, Do TH, Setty A, Le J.
    Pharmacotherapy; 2024 Aug 18; 44(8):606-614. PubMed ID: 36571459
    [Abstract] [Full Text] [Related]

  • 7. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O, Montakantikul P, Houngsaitong J, Kiratisin P, Sonthisombat P.
    Int J Infect Dis; 2016 Sep 18; 50():23-9. PubMed ID: 27418581
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.
    Kowalska-Krochmal B, Mączyńska B, Rurańska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M, Górzyńska A, Laufer K, Woronowicz K, Łubniewska J, Łappo J, Czwartos M, Dudek-Wicher R.
    Pathogens; 2022 Nov 30; 11(12):. PubMed ID: 36558775
    [Abstract] [Full Text] [Related]

  • 9. The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing Escherichia coli in ICU Patients Using Monte Carlo Simulation.
    Win EE, Htun KW, Tragulpiankit P, Tangtrakultham S, Montakantikul P.
    Infect Drug Resist; 2022 Nov 30; 15():439-453. PubMed ID: 35177911
    [Abstract] [Full Text] [Related]

  • 10. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
    Saelim W, Changpradub D, Thunyaharn S, Juntanawiwat P, Nulsopapon P, Santimaleeworagun W.
    Infect Chemother; 2021 Mar 30; 53(1):128-140. PubMed ID: 34409786
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli.
    Jitaree K, Sathirakul K, Houngsaitong J, Asuphon O, Saelim W, Thamlikitkul V, Montakantikul P.
    Antibiotics (Basel); 2019 Aug 22; 8(3):. PubMed ID: 31443514
    [Abstract] [Full Text] [Related]

  • 13. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B, Walker SAN.
    Eur J Clin Pharmacol; 2021 Feb 22; 77(2):197-205. PubMed ID: 32975650
    [Abstract] [Full Text] [Related]

  • 14. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G, Yu W, Cui Y, Shi Q, Huang C, Xiao Y.
    BMC Infect Dis; 2021 Mar 26; 21(1):307. PubMed ID: 33771113
    [Abstract] [Full Text] [Related]

  • 15. Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W, Changpradub D, Thunyaharn S, Hemapanpairoa J.
    Antibiotics (Basel); 2019 Nov 29; 8(4):. PubMed ID: 31795437
    [Abstract] [Full Text] [Related]

  • 16. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.
    Rodríguez-Gascón A, Canut-Blasco A.
    Rev Esp Quimioter; 2019 May 29; 32 Suppl 1(Suppl 1):19-24. PubMed ID: 31131588
    [Abstract] [Full Text] [Related]

  • 17. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W, Changpradub D, Hemapanpairoa J, Thunyaharn S.
    Infect Chemother; 2021 Sep 29; 53(3):503-511. PubMed ID: 34405596
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY, Xie M, Gong J, Yu N, Wei R, Lei LL, Zhao SM, Li RM, Dong X, Zhang XL, Zhou Y, Li SL, Cui YM.
    Front Pharmacol; 2023 Sep 29; 14():1132367. PubMed ID: 37188268
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.